- Home
- CZNC vs MREO Comparison
CZNC vs MREO Comparison
Compare CZNC & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CZNC | MREO |
|---|---|---|
| Founded | 1864 | 2015 |
| Country | United States | United Kingdom |
| Employees | 386 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 360.5M | 324.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CZNC | MREO |
|---|---|---|
| Price | $20.25 | $2.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $22.00 | $7.40 |
| AVG Volume (30 Days) | 49.1K | ★ 2.0M |
| Earning Date | 01-22-2026 | 11-10-2025 |
| Dividend Yield | ★ 5.53% | N/A |
| EPS Growth | ★ 22.09 | N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $109,632,000.00 | $500,000.00 |
| Revenue This Year | $5.72 | N/A |
| Revenue Next Year | $7.18 | $131.12 |
| P/E Ratio | $11.55 | ★ N/A |
| Revenue Growth | ★ 7.59 | N/A |
| 52 Week Low | $17.85 | $1.47 |
| 52 Week High | $22.68 | $3.94 |
Technical Indicators
Market Signals| Indicator | CZNC | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 57.34 | 63.14 |
| Support Level | $19.92 | $1.74 |
| Resistance Level | $20.67 | $2.18 |
| Average True Range (ATR) | 0.49 | 0.12 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 71.94 | 72.73 |
Price Performance
Historical ComparisonAbout CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).